Navigation Links
FDA Clears the Pathwork(R) Tissue of Origin Test for Hard-To-Identify Tumors
Date:7/31/2008

Pathwork Diagnostics' Gene Expression Test Is the First to Receive FDA Clearance for Diagnosis of Uncertain Tumors; Problem Affects 200,000 New

U.S. Cancer Cases Annually

SUNNYVALE, Calif., July 31 /PRNewswire/ -- Pathwork Diagnostics, Inc., a molecular diagnostics company focused on oncology, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Pathwork(R) Tissue of Origin Test for use in determining the origin of uncertain tumors. The test analyzes a tumor's gene expression pattern to help pinpoint the source of hard-to-identify tumors and is the first test of its kind to receive FDA clearance. Up to an estimated 200,000 newly diagnosed cancer patients annually in the U.S. may have a tumor for which the site of origin is uncertain after the initial diagnostic workup.(1,2,3,4) The FDA's clearance underscores the growing role that patients' genomic information can play in helping physicians make better decisions.

"Knowing the primary tumor site with greater certainty enables more appropriate cancer treatment. The growing trend in cancer care is the use of therapies that target specific tissues and their genomic components, rather than relying on a one-size-fits-all treatment approach," said Deborah J. Neff, President and Chief Executive Officer of Pathwork Diagnostics. "We believe the Pathwork Tissue of Origin Test will help provide more certainty in tumor diagnosis, which will enable more patients to realize the benefits of this new era in genomics-based diagnostics." The FDA-cleared Pathwork Tissue of Origin Test will be available as an in vitro diagnostic (IVD) kit, meaning that clinical laboratories can run the test themselves. The test is currently available as a service through Pathwork's CLIA-certified laboratory.

The Pathwork Tissue of Origin Test uses a microarray to measure the expression pattern, comprising more than 1,500 genes, in the uncertain tumor and compares it to e
'/>"/>

SOURCE Pathwork Diagnostics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. FDA Clears ExAblate Fertility Enhancement Study in Women With Uterine Fibroids
2. FDA Clears Advanced Test for Monitoring Metastatic Colorectal Cancer
3. Childrens Brain Tumor Foundations Tissue Bank Consortium May Solve Dire Problem in Pediatric Cancer Research
4. Newly Published Study Shows OPKOs siRNA Bevasiranib Is Taken Up by Target Tissues in the Eye
5. Phase I/II Study of Targeted Gene Delivery In Vivo - Intravenous Infusions of REXIN-G - Demonstrates Dose-Dependent Anti-Tumor Activity Without Toxicity in Patients With Progressive Chemo-Resistant Bone and Soft Tissue Sarcoma (ASCO 2008)
6. Cardium and Tissue Repair Companys Excellarate Candidate for Healing Diabetic Wounds Gains Media Focus in Multiple Regions Across U.S.
7. Study Finds Starion Instruments Tissue Welding Technology Safe and Effective in Parotidectomy Procedures
8. Knee Pain? An Exclusive Study Engineers Cartilage to Match Patients Own Tissue
9. Study of Pathwork Diagnostics Tissue of Origin Test Published in the Journal of Molecular Diagnostics: Investigates Test Reproducibility in Multiple Labs to Determine Primary Tumor in Cancer Cases
10. Raydiance Collaborates With Rutgers University and Nations Largest Tissue Bank to Develop Innovative Tissue Processing Approaches
11. Study Finds Starion Instruments Tissue Welding Technology Reduces Pain and Bleeding in Tonsillectomy Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 2013  Omeros Corporation (NASDAQ: OMER ... Application (IND) to evaluate OMS824 in Huntington,s disease ... Drug Administration (FDA). OMS824 selectively inhibits phosphodiesterase 10 ... brain linked to a wide range of diseases ... OMS824 has shown promising results in animal models ...
(Date:5/23/2013)... -- Echo Pharma Acquisition Limited ("Royalty Pharma") announced today that ... from 90 percent to 50 percent of Maximum Elan ... the terms of the Revised Offer Document issued today, ... the terms of the Increased Offer, Royalty Pharma is ... for $12.50 per share in cash. The Increased Offer ...
(Date:5/23/2013)... Engeland, May 23, 2013 Nederland ... met lagere urinewegsymptomen geassocieerd met BPH Astellas ... dochteronderneming van Astellas Pharma Inc, gebaseerd in ... kondigde vandaag aan dat het Nederlandse College ter Beoordeling ... in Nederland. De handelsvergunning verleend voor VESOMNI ...
Breaking Medicine Technology:Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 2Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 3Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 4Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 2Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 3Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 4Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 5Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 6Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 7Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 8Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 9Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 10Astellas ontvangt handelsvergunning voor VESOMNITM van Nederlandse College ter Beoordeling van Geneesmiddelen 2Astellas ontvangt handelsvergunning voor VESOMNITM van Nederlandse College ter Beoordeling van Geneesmiddelen 3Astellas ontvangt handelsvergunning voor VESOMNITM van Nederlandse College ter Beoordeling van Geneesmiddelen 4
(Date:5/23/2013)... May 23, 2013 A medical malpractice ... Court (reference number 110504/2009) by Lori Mandel, an office ... Ms. Mandel $8.6 million. Ms. Mandel sought the medical ... led to further complications that affected the quality of ... , The plaintiff alleged that her doctor rendered conservative ...
(Date:5/23/2013)... May 23 2013 - New techniques in imaging ... from McGill University,s Montreal Neurological Institute, and his ... from epilepsy. The combination of electroencephalogram (EEG) ... more precise localization of the areas generating epileptic ... optimal ways of intervention, if appropriate. These ...
(Date:5/23/2013)... 2013 According to a new market ... Management; Subscriber Data Management (SDM); Telecom Application Server; Service ... (2013 – 2018)", published by MarketsandMarkets, the SDP Market ... a CAGR of 9.15% from 2013 to 2018. , ... , 84 Figures , 189 ...
(Date:5/23/2013)... Miami, FL (PRWEB) May 23, 2013 In ... in 7 years. This doesn’t mean, however, that Florida’s good ... National Hurricane Center . This year, he encourages residents, it ... During hurricane season 2013, forecasters are predicting there to be ... reports WUFT . With hurricane season lasting from June ...
(Date:5/23/2013)... Worldwide Power Products (WPP), a power-generation ... has licensed the rights to sell Hythane Company's ... burn a mixture of natural gas and diesel. WPP ... for sale and rental and will also sell ... WPP's service technicians will be certified to install the ...
Breaking Medicine News(10 mins):Health News:New York Law Journal Releases Top Medical Malpractice Case for 2012: NY Supreme Court Awards $8.6 Million to Plaintiff after Doctor's Misdiagnosis Led to Personal Injury 2Health News:New York Law Journal Releases Top Medical Malpractice Case for 2012: NY Supreme Court Awards $8.6 Million to Plaintiff after Doctor's Misdiagnosis Led to Personal Injury 3Health News:New imaging techniques used to help patients suffering from epilepsy 2Health News:Service Delivery Platform (SDP) Market Is Growing at a CAGR of 9.15% & to Reach $6.94 Billion by 2018 - New Report by MarketsandMarkets 2Health News:Service Delivery Platform (SDP) Market Is Growing at a CAGR of 9.15% & to Reach $6.94 Billion by 2018 - New Report by MarketsandMarkets 3Health News:As Hurricane Season Nears, Skylake Insurance Encourages Florida Residents To Prepare Early For Safety 2Health News:Worldwide Power Products Announces Partnership with Hythane Company to Offer OptiBlend™ Bi-Fuel Solution for Diesel Engines 2Health News:Worldwide Power Products Announces Partnership with Hythane Company to Offer OptiBlend™ Bi-Fuel Solution for Diesel Engines 3
... The Health Minister Iris Evans says that Albertans are hoping for ... ,On the other hand the Albertans are known ... has prepared the initial phase of the new health care plan ... also plans to introduce more reforms by the end of the ...
... be used for regeneration of broken bones in a new ... headed by York University and // researchers from UK and ... biology, sociology and Philosophy from York University is aimed at ... the treatment of bone defects and fractures. ,Professor ...
... India as eliminated Leprosy but still we have to eradicate ... increasing the awareness regarding the // transmission of the bacteria ... disease. ,Indian Health Minister Dr. Anbumani Ramadoss during ... completely eradicate the disease which as about a 1 Lakh ...
... Doctors in New South Wales are angry at a proposal to ... Carroll, spokesman for the medical staff council at Wagga // Base ... elective surgery every fourth Friday. ,"So it'd create a ... relatively small amount of money but at great cost to patient ...
... University of Texas has revealed that moderate physical activity ... in easing depression. // Other measures adopted by ... smoking are associated with adverse health effects. ... 40 individuals, diagnosed with depression. None of the study ...
... study conducted on the prevalence of diabetes in the Indian ... has been uncovered. // So far, such studies have ... cannot be applied to South Asians. ,The research ... Diabetes Research Centre, an association of the World Health Organization ...
Cached Medicine News:Health News:Prevention And Control Of Diabetes Crucial To Indian Population 2
Used to introduce balloon, closed and non-tapered end catheters or other devices for intervention....
Used to introduce balloon, electrode, closed or non-tapered end catheters and other devices for intervention....
Used to introduce large balloon, closed and non-tapered end catheters or other devices for intervention....
Used to introduce large devices for vascular intervention....
Medicine Products: